Lupin Awaits 'Clarity' On Albuterol Filing

Says Other US Launches On Track Despite Deferred FDA Inspections

 
• By Vibha Ravi
  
Generate a summary of this article
Listen to this article
Beta

After lower growth in its India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.

Hands holding rope forming arrow pointing upwards - Image
Lupin Counting On New Products To Change US Growth Trajectory • Source: Shutterstock

Lupin is on track with timelines for new product launches and expects US Food and Drug Administration (FDA) approval for its generic version of Teva's ProAir (albuterol sulfate metered dose inhaler) in the first half of its fiscal 2021. The key asset is expected to help propel the Indian firm’s growth in the inhalation segment in the US, but approval timelines have been somewhat unclear thus far.

Lupin's plans for a launch in FY20 were derailed by a complete response letter (CRL). “We responded to the CRL...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business